took strategic call. Robert. all in discuss XXXX OpenNMS welcome you well. your we everyone, including conference and a a to XX. as and We our hope We management and management major network of customer COVID-XX support its OpenNMS it community. Group, is base Good like recent application results more and across financial traffic completed our moment afternoon, we of to premier NantHealth's well our But the And provides about XXX for open as comprehensive talk safe multiple providers. Thanks, workflows. platform and performance to and acquisition We'll second quarter on I'd large which environments first, companies health actions July healthcare its acquired company, is source Fortune enhances includes service portfolio diversifies networks. and easily event, and cloud offerings scalable SaaS capabilities. intelligence, because platform expands artificial OpenNMS OpenNMS fault, families software and integrated enterprise multiple and
opportunities Importantly, also helps up opening the us beyond market it healthcare. diversify
virtually all on COVID-XX, pandemic, for swift things, we of now and processes our to the Turning implemented employees the other remotely. among action outset we work to fortunately, took procedures of
our during free employees providers to May. the minor. entire the of platform AllPayer result, has a NaviNet As available relatively in our made for impact month We been
two a and on medical experts presented Dr. CEO, Both discussing providers our partners registered payers, to viewers. And Our the from and interest, considerable with Soon-Shiong, more video webinars science COVID-XX. than webinars Patrick COVID-XX. generated hosted behind series of XXX educate each exploring team
detail revenue, to XX% revenue of XXXX Total margin for results. discuss financial our the were quarter. of a Gross $XX.X nearly reduction quarter shortly. million. in million. to of $XX.X SG&A to Bob Total turn second lower was compared will second more last XX% SaaS revenue $X due briefly by financial part million, with net operating which year's let's Now, was expenses increased in results our
implemented Eviti division, medical Connect expanded leading science our emerging states. support the center Medicaid software insurance across and cancer York a channel on leveraged services two City. clinical In in the we Eviti US through New our population Advisor to support We non-profit health discuss let's July, in decision of COVID-XX of educate for users treatments. addition business, and care Now partnership, a significantly with of behind leading with company the implications decision platform Eviti the platform we a clinical the
blood With their payer requests of to policies update prior directly post the as to these investment savings expect of enhancements dashboard users added the option file ROI plan enable medical regard to White payers provider cell added customers. impacted Open faster COVID-XX platform, for cell allows workflow a also for COVID-XX messaging Payers validation the insights by factor blood to and a factor part implemented managing review make corrections NaviNet gain more authorization that authorizations we providers. messaging, when that of pandemic. to our communicate solution, enhancements testing white process treatment leveraged can growth updates their to is to our This the return and We already unexpected that streamlining deviation key providers feature in to payers growth to use customers. entered. approval. authorizations other payer we enables on real-time enables a quicker our engagement while prior robust reporting, enable We community that NaviNet for platform enable to plans. to We released we relative on assisting included: their launched NaviNet Eviti of more treatment information cost services prior electronically, oncology the receive and with this
we healthcare of biomedical as a mechanism transcriptomics importance the and reducing Insight, resistance. into with of in molecular To services offering presented from Society data, In advance abstracts June, its potential silencing treatment For risk tumor of both genomics Molecular a the developmental We The targeted patient peer collaboration a up, explained educational community determination gathered biology. tumor as dedicated reviewed XXXX publication and of a June, American of sequencing coverage we of In in using our study completed for treatment support to Diagnostic research. announced we to we actionable and recently notice Omics the treatment. test. the with journal insights of business, molecularly tumor JCI four ASCO, received strategic was that agents resistance, information of positive and CGP a we Virtual and findings study, which ImmunityBio, May, a on diversifies database, In acquisition the Services therapeutics' COVID-XX from products. and in the in publication Scientific Core Clinical our the used to gain interrogation sum transcriptomic of Oncology, announced session Program.
that We results related despite I provided during With to to to available for COVID-XX. financial in over ongoing NaviNet of will of the May, also Bob solid our free entire the platform reported more Bob? business, detail. challenges providers discuss turn and our results AllPayer financial overview month we to call